Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2011 1
2014 1
2017 1
2018 1
2023 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
Genome diversity of Leishmania aethiopica.
Hadermann A, Heeren S, Maes I, Dujardin JC, Domagalska MA, Van den Broeck F. Hadermann A, et al. Among authors: heeren s. Front Cell Infect Microbiol. 2023 Apr 20;13:1147998. doi: 10.3389/fcimb.2023.1147998. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37153154 Free PMC article.
Diversity and dissemination of viruses in pathogenic protozoa.
Heeren S, Maes I, Sanders M, Lye LF, Adaui V, Arevalo J, Llanos-Cuentas A, Garcia L, Lemey P, Beverley SM, Cotton JA, Dujardin JC, Van den Broeck F. Heeren S, et al. Nat Commun. 2023 Dec 15;14(1):8343. doi: 10.1038/s41467-023-44085-2. Nat Commun. 2023. PMID: 38102141 Free PMC article.
Genome Analysis of Triploid Hybrid Leishmania Parasite from the Neotropics.
Van den Broeck F, Heeren S, Maes I, Sanders M, Cotton JA, Cupolillo E, Alvarez E, Garcia L, Tasia M, Marneffe A, Dujardin JC, Van der Auwera G. Van den Broeck F, et al. Among authors: heeren s. Emerg Infect Dis. 2023 May;29(5):1076-1078. doi: 10.3201/eid2905.221456. Emerg Infect Dis. 2023. PMID: 37081624 Free PMC article.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762-8. Online ahead of print. Lancet. 2024. PMID: 39581202
11 results